![Mark to Market artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts113/v4/8b/5d/d0/8b5dd07f-d0c3-b308-8b64-6f421c7a8316/mza_9689604371728346307.jpg/100x100bb.jpg)
109: Aurobindo's US outlook improves but earnings may just be steady
Mark to Market
English - November 17, 2020 08:17 - 5 minutes - 5.19 MBBusiness News News market price finance podcast investing stock market entrepreneurship business business podcast money market share market entrepreneur Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Investors are banking on Aurobindo’s US pharma revenues getting a boost on the back of improving injectable sales in the second quarter. But a part of that growth already seems to be reflecting in the stock price gains of about 86% in 2020. Find more details in this podcast. Listen in.